Pre-Approval Information Exchange Act of 2022
This bill specifies that product information that is exchanged between drug manufacturers and certain health care entities (e.g., formulary committees) about drug products before regulatory approval is not considered to be misbranding if it relates to the product's investigational use and meets other specified criteria. The Government Accountability Office must study the use and effects of such information.
| Action Date | Type | Text | Source |
|---|---|---|---|
| 2022-11-16 | Committee | Referred to the Subcommittee on Health. | House committee actions |
| 2022-11-15 | IntroReferral | Referred to the House Committee on Energy and Commerce. | House floor actions |
| 2022-11-15 | IntroReferral | Introduced in House | Library of Congress |